List of Excipients in Branded Drug LEVAMLODIPINE

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Xspire Pharma LLC	LEVAMLODIPINE	levamlodipine	42195-425	BETADEX
Xspire Pharma LLC	LEVAMLODIPINE	levamlodipine	42195-425	CELLULOSE, MICROCRYSTALLINE
Xspire Pharma LLC	LEVAMLODIPINE	levamlodipine	42195-425	MAGNESIUM STEARATE
Xspire Pharma LLC	LEVAMLODIPINE	levamlodipine	42195-425	SILICON DIOXIDE

Levamlodipine Excipient Strategy and Commercial Opportunities

Last updated: November 1, 2026

Levamlodipine, the S-enantiomer of amlodipine, is primarily commercialized as levamlodipine besylate in oral immediate-release products. The strongest near-term opportunities are differentiated tablets, orally disintegrating tablets, pediatric liquid formulations, and fixed-dose combinations. The main development risks are low-dose content uniformity, enantiomeric purity, dissolution control, regulatory classification against racemic amlodipine, and limited United States market precedent.

What is levamlodipine and how does it differ from amlodipine?

Levamlodipine is the pharmacologically active S-enantiomer of amlodipine. Commercial amlodipine products, including Norvasc, historically contain racemic amlodipine, generally administered as amlodipine besylate.[1]

Attribute	Levamlodipine	Racemic amlodipine
Chemical identity	S-amlodipine	R/S amlodipine mixture
Common salt	Levamlodipine besylate	Amlodipine besylate
Pharmacology	Calcium-channel blocker	Calcium-channel blocker
Typical dose range	Often 2.5 mg or 5 mg, depending on market	Commonly 2.5 mg, 5 mg, or 10 mg
Primary dosage form	Immediate-release tablet	Immediate-release tablet
Main therapeutic use	Hypertension and related cardiovascular indications	Hypertension and angina
Regulatory benchmark	Must be assessed by jurisdiction	Established reference products in multiple markets
Core formulation issue	Uniform distribution of a low-dose chiral API	Low-dose uniformity and dissolution

Levamlodipine is not simply a lower-strength version of racemic amlodipine. Developers must establish the identity, purity, assay, dissolution, stability, and clinical or bridging basis for the single-enantiomer product under the applicable regulatory pathway.

What excipients are best suited to levamlodipine tablets?

Immediate-release tablets are the lowest-risk platform for levamlodipine. A conventional dry-granulation or direct-compression formula can use a water-soluble diluent, a compression aid, a superdisintegrant, a glidant, a lubricant, and a protective film coat.

Recommended immediate-release excipient architecture

Formulation function	Suitable excipient classes	Commercial rationale
Dilution and dose uniformity	Microcrystalline cellulose, lactose monohydrate, mannitol	Increases blend mass and improves low-dose content uniformity
Compression	Microcrystalline cellulose, anhydrous lactose, dibasic calcium phosphate	Supports robust tablet manufacture
Disintegration	Crospovidone, croscarmellose sodium, sodium starch glycolate	Supports rapid release without complex processing
Flow improvement	Colloidal silicon dioxide	Reduces segregation and improves hopper flow
Lubrication	Magnesium stearate, sodium stearyl fumarate	Controls ejection force and sticking
Wet granulation binder	Povidone, hypromellose, pregelatinized starch	Useful when direct compression produces poor uniformity
Film coating	Hypromellose, polyvinyl alcohol, polyethylene glycol, titanium dioxide or approved colorants	Improves handling, identification, and light protection

The formulation should be designed around the active concentration rather than the nominal tablet strength. A 2.5 mg tablet can contain less than 1% active pharmaceutical ingredient by weight. That creates a higher risk of segregation, assay variability, and content-uniformity failures than a 5 mg or 10 mg tablet.

A practical approach is to prepare an API premix with a portion of microcrystalline cellulose or lactose before final blending. Geometric dilution, controlled blend time, low-shear transfer, and validated hold times are more important than maximizing tablet hardness.

Which excipients should be screened first?

The initial screening set should include:

1. Microcrystalline cellulose with crospovidone and magnesium stearate.
2. Lactose monohydrate with croscarmellose sodium.
3. Mannitol-based formulations for orally disintegrating or chewable products.
4. Anhydrous lactose or dibasic calcium phosphate where moisture control is critical.
5. Sodium stearyl fumarate where magnesium-stearate sensitivity or dissolution retardation is observed.

The selection should be based on blend uniformity, tablet weight variation, dissolution, impurity growth, and stability under accelerated conditions. Excipients should not be selected only on the basis of tablet hardness or initial dissolution.

How do solubility and pH affect levamlodipine formulation design?

Amlodipine is a weakly basic dihydropyridine calcium-channel blocker. Its ionization profile can make dissolution and apparent solubility sensitive to pH. The besylate salt improves handling and supports oral solid-dose manufacture, but salt conversion, microenvironmental pH, and precipitation during dissolution remain relevant development variables.[2]

The formulation should avoid unnecessary alkalinity. Alkaline excipients can alter the salt state and may change dissolution behavior or stability. Developers should screen:

• Microenvironmental pH after compression.
• Dissolution in acidic, intermediate, and near-neutral media.
• Precipitation after transfer from acidic gastric conditions.
• Compatibility with alkaline lubricants or mineral excipients.
• Photostability and moisture sensitivity of the finished product.

A balanced formulation normally uses neutral or mildly acidic excipient systems, rapid disintegration, and packaging that limits moisture and light exposure. The final decision should be based on stability and dissolution data rather than a general preference for one filler.

What formulation patents could protect levamlodipine products?

The original composition-of-matter and salt protection surrounding amlodipine is generally old and is unlikely to provide a new-term barrier for a modern levamlodipine product. Commercial value is more likely to come from narrower formulation, manufacturing, or use claims.

Potential patentable subject matter includes:

Patent category	Possible claim focus	Relative commercial value
Enantiomeric composition	High-purity S-amlodipine or defined impurity profile	Moderate if purity is technically difficult
Particle engineering	Particle-size distribution, morphology, or surface treatment	Moderate
Low-dose uniformity	Premix, granulation, or blending process	Moderate to high if process-specific
Orally disintegrating tablet	Mannitol-based matrix, taste masking, disintegration time	High for differentiated products
Liquid formulation	Solubilization, suspension stability, preservative system	Moderate to high
Fixed-dose combination	Levamlodipine with an angiotensin receptor blocker, statin, or diuretic	Potentially high, subject to jurisdiction and prior art
Modified release	Release-control matrix or multiparticulate system	Selective; clinical value must justify complexity
Manufacturing process	Resolution, chiral enrichment, crystallization, or salt formation	High if it reduces cost or improves purity
Method of treatment	Defined patient population, dose, or tolerability benefit	Variable and jurisdiction-dependent

A patent estate built only around a standard levamlodipine tablet is likely to face substantial obviousness and enablement scrutiny. Stronger protection would link the formulation to a measurable technical result, such as improved content uniformity, reduced degradation, faster disintegration, improved bioavailability, or a defined impurity profile.

What is the FDA and Orange Book status of levamlodipine?

The FDA Orange Book is organized around approved drug products and their listed patents and exclusivities. Through June 2024, the principal U.S. regulatory reference for amlodipine was racemic amlodipine, including amlodipine besylate products. A separate, widely established FDA-approved reference product for levamlodipine was not identified in the standard FDA approval databases.[3,4]

This has several consequences:

• A levamlodipine product cannot automatically assume an ANDA pathway merely because racemic amlodipine is approved.
• The active ingredient, enantiomeric composition, dosage form, and reference-product relationship must be analyzed together.
• A 505(b)(2) strategy may be relevant where the sponsor relies partly on published data or an FDA-approved product but introduces a scientifically distinct active ingredient or formulation.
• Orange Book patent certifications and Paragraph IV litigation depend on the specific reference product and listed patents.
• FDA approval of racemic amlodipine does not itself establish interchangeability with levamlodipine.

The regulatory pathway is therefore a central commercial issue. A sponsor should not treat levamlodipine as an ordinary generic version of amlodipine without confirming the FDA’s reference-product and application requirements.

When does levamlodipine lose exclusivity and when could generics enter?

There is no single global levamlodipine exclusivity date. The answer depends on the country, product, patent family, regulatory approval date, and whether the product relies on new clinical or formulation data.

United States

For a new U.S. levamlodipine product, relevant exclusivity could include:

• Five-year new chemical entity exclusivity if the FDA treats the active ingredient as eligible.
• Three-year exclusivity for qualifying new clinical investigations supporting a change.
• Orphan-drug exclusivity if the product meets orphan criteria.
• Pediatric exclusivity if awarded under the applicable program.
• Patent protection for composition, formulation, method of use, or manufacturing claims.

The precise treatment of an enantiomer relative to an already approved racemate is a technical regulatory question. It should be resolved through FDA pathway analysis and cannot be inferred solely from the approval history of racemic amlodipine.

Other markets

Levamlodipine has had commercial presence in certain Asian markets, including products marketed under national approval systems. Patent and data-exclusivity outcomes vary substantially. In some markets, commercial entry may depend more on formulation differentiation, local registration requirements, physician adoption, and reimbursement than on remaining patent term.

What Paragraph IV challenges and litigation risks exist?

A Paragraph IV challenge is relevant only if a product is submitted against an FDA-listed reference product with applicable Orange Book patents. Because a separate, broadly established U.S. levamlodipine reference product was not identified through June 2024, there is no clear, standard levamlodipine Paragraph IV pathway comparable to a conventional generic challenge against an Orange Book-listed brand.

Potential U.S. litigation risks would arise if:

• A levamlodipine product is approved through a pathway linked to a reference product with listed patents.
• A sponsor seeks approval for a formulation covered by an unexpired listed patent.
• A branded levamlodipine product obtains patents for a fixed-dose combination or method of treatment.
• A generic sponsor launches after approval while facing non-Orange Book patent claims.

In markets where levamlodipine products already exist, disputes may focus on process patents, formulation patents, trademark rights, regulatory data, and local patent linkage rules.

No major publicly documented settlement agreement can be assigned confidently to a single global levamlodipine patent dispute without a jurisdiction-specific litigation review.

How strong is the levamlodipine patent estate?

The estate is likely strongest in three areas: stereoselective manufacturing, differentiated dosage forms, and fixed-dose combinations.

Estate component	Expected strength	Main vulnerability
Basic levamlodipine composition	Low to moderate for new entrants, depending on jurisdiction	Age of foundational amlodipine disclosures
Besylate salt	Low if based on old salt chemistry	Expired or vulnerable prior art
Standard immediate-release tablet	Low	Routine excipient and process combinations
ODT or taste-masked product	Moderate to high	Obviousness and overlapping prior art
Pediatric liquid or suspension	Moderate	Predictable excipient selection
Chiral manufacturing	Moderate to high	Reproducibility and enablement
Fixed-dose combinations	Moderate to high	Known combinations and obviousness
Specific method of use	Variable	Written-description and clinical-support requirements

A commercial sponsor should prioritize claims tied to a product specification that competitors cannot easily design around. A claim to “levamlodipine with a disintegrant” is weaker than a claim that defines a narrow composition, manufacturing sequence, dissolution profile, impurity limit, and demonstrated stability advantage.

What commercial opportunities exist for levamlodipine excipient innovation?

Orally disintegrating tablets

An ODT could improve administration for elderly patients, patients with dysphagia, and patients who have difficulty swallowing conventional tablets. Mannitol, crospovidone, low-substituted hydroxypropyl cellulose, and taste-masking technologies are likely candidates.

The commercial opportunity is strongest where the product delivers:

• Less than 30 seconds disintegration.
• Acceptable mouthfeel.
• Low friability.
• Stable low-dose content uniformity.
• Packaging that protects against humidity.
• A clear clinical or adherence benefit.

Pediatric oral liquids

A levamlodipine suspension or solution could address dose flexibility and swallowing barriers. A suspension may be easier to develop than a true solution if solubilization requires a high cosolvent or surfactant burden.

Key excipient issues include:

• Sedimentation and redispersibility.
• Preservative effectiveness.
• pH control.
• Taste masking.
• Container compatibility.
• Dose accuracy at small administration volumes.

Pediatric development requires more than a liquid dosage form. The formulation must support accurate dosing with an oral syringe and demonstrate acceptable safety for the target age group.

Fixed-dose combinations

Levamlodipine may be paired commercially with antihypertensive agents such as losartan, valsartan, telmisartan, olmesartan, or hydrochlorothiazide, depending on local treatment guidelines. Fixed-dose combinations can support brand differentiation, but they introduce compatibility, dissolution, dose-ratio, and regulatory bridging requirements.

The strongest opportunity is a combination that solves a documented adherence or titration problem. A simple duplication of an established amlodipine combination may have limited pricing power.

Modified-release products

Modified release is technically possible but commercially less compelling for a drug that already has a long effective duration of action. A release-control product would need to show a clinical benefit, reduced adverse effects, improved adherence, or a meaningful pharmacokinetic advantage. Otherwise, the development cost and regulatory burden may exceed the value of the differentiation.

How does levamlodipine compare with competing calcium-channel blockers?

Product	Main commercial advantage	Excipient opportunity	Competitive limitation
Levamlodipine	Single-enantiomer positioning and lower nominal dose	ODT, liquid, combination tablet	Limited U.S. reference-product precedent
Racemic amlodipine	Broad approval and physician familiarity	Low-cost generic tablets and combinations	Mature competition
Felodipine	Extended-release positioning	Controlled-release matrix	More complex formulation
Lercanidipine	Differentiated lipophilicity and regional use	Immediate-release and combination products	Market access varies
Nifedipine	Established modified-release products	Osmotic or matrix systems	Extensive generic competition

Levamlodipine is more likely to win through dosage-form convenience, combination positioning, or manufacturing economics than through a basic tablet alone.

What manufacturing and IP barriers affect commercial entry?

The most important manufacturing barriers are:

• Achieving consistent enantiomeric purity.
• Controlling low-dose blend uniformity.
• Preventing segregation during scale-up and transfer.
• Controlling polymorphic or solid-state behavior.
• Maintaining dissolution after coating and storage.
• Demonstrating stability under heat, humidity, and light.
• Establishing a reproducible chiral assay and impurity method.

For an excipient-led product, the manufacturing process should be developed together with the patent strategy. A process that depends on a specific premix ratio, granulation endpoint, particle-size range, or order of addition can support both product robustness and process claims.

What licensing opportunities exist for levamlodipine?

No major global licensing transaction can be identified as the standard commercial model for levamlodipine. The more realistic licensing opportunities are:

• Regional rights to an approved levamlodipine product.
• A license to a chiral-enrichment or crystallization process.
• An ODT or pediatric liquid platform.
• A fixed-dose combination dossier.
• Contract development and manufacturing rights.
• Technology transfer for low-dose uniformity or stability improvement.

A license is more defensible when it includes regulatory data, manufacturing know-how, validated analytical methods, or market authorization rather than only a broad formulation patent.

What generic launch scenarios are most likely?

Scenario	Timing driver	Commercial impact
Standard immediate-release tablet	Local patent and approval status	Rapid price competition
ODT launch	Formulation patent and regulatory approval	Moderate differentiation
Pediatric liquid launch	Data package and market need	Higher development barrier
Fixed-dose combination	Combination patent and clinical positioning	Potentially stronger margins
Process-based low-cost entrant	Manufacturing efficiency	Margin pressure across the category

The highest-risk product for an incumbent is a low-cost immediate-release tablet that matches the established dose and supply channel. The strongest defensive strategy is a layered estate covering formulation, process, combination use, trade dress, and regulatory data.

Key Takeaways

• Levamlodipine is the S-enantiomer of amlodipine and is usually supplied as levamlodipine besylate.
• Immediate-release tablets remain the lowest-risk formulation platform.
• Low-dose blend uniformity is the central excipient and manufacturing challenge.
• Microcrystalline cellulose, lactose, mannitol, crospovidone, croscarmellose sodium, colloidal silicon dioxide, and magnesium stearate are logical starting materials for development.
• ODTs, pediatric liquids, and fixed-dose combinations offer stronger commercial differentiation than a conventional tablet.
• A standard levamlodipine tablet is unlikely to support a strong new patent position without a defined technical advantage.
• Through June 2024, a separate widely established FDA-approved levamlodipine reference product was not identified in the standard FDA databases.
• A Paragraph IV strategy cannot be assumed from the approval status of racemic amlodipine.
• The most defensible IP opportunities involve chiral manufacturing, low-dose uniformity, differentiated delivery, and combination products.
• Licensing value is likely to reside in regulatory dossiers, manufacturing know-how, and differentiated dosage forms.

FAQs About Levamlodipine Formulation and Commercialization

Is levamlodipine the same as amlodipine besylate?

No. Amlodipine besylate generally refers to the besylate salt of racemic amlodipine, while levamlodipine besylate contains the S-enantiomer.

Can levamlodipine be formulated as an oral solution?

Yes, but a solution requires control of pH, solubilization, precipitation, taste, preservative performance, and container compatibility. A suspension may be more practical where complete solubilization is difficult.

Which excipient is best for levamlodipine content uniformity?

No single excipient is universally best. Microcrystalline cellulose or lactose used in a validated premix and geometric-dilution process is a practical starting strategy for low-dose uniformity.

Does racemic amlodipine approval create automatic interchangeability for levamlodipine?

No. Regulatory interchangeability depends on the jurisdiction, active-ingredient determination, reference product, application pathway, and supporting evidence.

Is a levamlodipine ODT commercially more attractive than a standard tablet?

Usually, yes, if it produces a measurable convenience or adherence benefit and can maintain low-dose uniformity, taste acceptability, stability, and manufacturing yield.

References

1. U.S. Food and Drug Administration. (2022). Norvasc (amlodipine besylate) prescribing information.
2. National Center for Biotechnology Information. (2024). PubChem compound summary: Amlodipine. PubChem.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
4. U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs database.
5. International Council for Harmonisation. (2003). ICH Q6A: Specifications: Test procedures and acceptance criteria for new drug substances and new drug products.
6. United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary.